Carfilzomib: a novel second-generation proteasome inhibitor (Q33395298)

26 July 2017

Carfilzomib: a novel second-generation proteasome inhibitor (English)

1 reference

26 July 2017

Meaghan L Khan

1

1 reference

PubMed ID

21568676

26 July 2017

A Keith Stewart

series ordinal

2

1 reference

PubMed ID

21568676

26 July 2017

language of work or name

English

0 references

publication date

1 May 2011

1 reference

26 July 2017

1 reference

26 July 2017

7

1 reference

26 July 2017

5

1 reference

26 July 2017

607-612

1 reference

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

26 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3931449

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3931449

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3931449

Improved survival in multiple myeloma and the impact of novel therapies

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3931449

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3931449

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3931449

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3931449

The development of proteasome inhibitors as anticancer drugs

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3931449

The proteasome: a suitable antineoplastic target

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3931449

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3931449

Proteasome inhibitors: from research tools to drug candidates

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3931449

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3931449

Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3931449

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

14 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.2217%2FFON.11.42

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2217%2FFON.11.42

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2217%2FFON.11.42

Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates

21 January 2018

1 reference

PubMed

12 December 2020

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

1 reference

PubMed

12 December 2020

Proteolysis: from the lysosome to ubiquitin and the proteasome

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.2217/FON.11.42

1 reference

26 July 2017

1 reference

26 July 2017

1 reference

PubMed ID

21568676